Trabectedin, a drug acting on both cancer cells and the tumour microenvironment

Ecteinascidin 743 Interferes with the Activity of EWS-FLI1 in Ewing Sarcoma Cells

(2015) Patrick J. Grohar et al.   NEOPLASIA

Trabectedin and Plitidepsin: Drugs from the Sea that Strike the Tumor Microenvironment

(2014) Carlos Galmarini et al.   Marine Drugs

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

(2013) Giovanni Germano et al.   CANCER CELL

Dual Targeting of EWS-FLI1 Activity and the Associated DNA Damage Response with Trabectedin and SN38 Synergistically Inhibits Ewing Sarcoma Cell Growth

(2013) Patrick J. Grohar et al.   CLINICAL CANCER RESEARCH

13 years of trabectedin, 5 years of Yondelis®: what have we learnt?

(2013) Axel Le Cesne   Expert Review of Anticancer Therapy

Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: A retrospective, multicenter study

(2013) Gabriella Ferrandina et al.   GYNECOLOGIC ONCOLOGY

Comparison ofin vitroandin vivobiological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104)

(2013) Michela Romano et al.   INTERNATIONAL JOURNAL OF CANCER

Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials

(2013) José María del Campo et al.   MEDICAL ONCOLOGY

Altered expression of the miRNA processing endoribonuclease Dicer has prognostic significance in human cancers

(2012) Loredana Pellegrino et al.   Expert Review of Anticancer Therapy

PPARγ agonists enhance ET-743–induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma

(2012) Elizabeth Charytonowicz et al.   JOURNAL OF CLINICAL INVESTIGATION

Prospects and challenges for the development of new therapies for Ewing sarcoma

(2012) Patrick J. Grohar et al.   PHARMACOLOGY & THERAPEUTICS

XPF-Dependent DNA Breaks and RNA Polymerase II Arrest Induced by Antitumor DNA Interstrand Crosslinking-Mimetic Alkaloids

(2011) Sascha Feuerhahn et al.   CHEMISTRY & BIOLOGY

Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment

(2011) P. Allavena et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study

(2011) P. Schöffski et al.   EUROPEAN JOURNAL OF CANCER

Trabectedin in advanced uterine leiomyosarcomas: A retrospective case series analysis from two reference centers

(2011) Roberta Sanfilippo et al.   GYNECOLOGIC ONCOLOGY

A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: A gynecologic oncology group study

(2011) Bradley J. Monk et al.   GYNECOLOGIC ONCOLOGY

Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression

(2011) Mina J Bissell et al.   NATURE MEDICINE

Temperature-induced melting of double-stranded DNA in the absence and presence of covalently bonded antitumour drugs: insight from molecular dynamics simulations

(2011) Juan A. Bueren-Calabuig et al.   NUCLEIC ACIDS RESEARCH

Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells

(2010) G. Germano et al.   CANCER RESEARCH

Macrophage Diversity Enhances Tumor Progression and Metastasis

(2010) Bin-Zhi Qian et al.   CELL

A Review of Trabectedin (ET-743): A Unique Mechanism of Action

(2010) Maurizio D'Incalci et al.   MOLECULAR CANCER THERAPEUTICS

Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series

(2009) F. Grosso et al.   ANNALS OF ONCOLOGY

Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients

(2009) Antoine Hollebecque et al.   INVESTIGATIONAL NEW DRUGS

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors

(2009) C. Forni et al.   MOLECULAR CANCER THERAPEUTICS

Development of Yondelis® (trabectedin, ET-743). A semisynthetic process solves the supply problem

(2009) Carmen Cuevas et al.   NATURAL PRODUCT REPORTS

Von Hippel-Lindau-Coupled and Transcription-Coupled Nucleotide Excision Repair-Dependent Degradation of RNA Polymerase II in Response to Trabectedin

(2008) G. J. Aune et al.   CLINICAL CANCER RESEARCH

Role of homologous recombination in trabectedin-induced DNA damage

(2008) M. Tavecchio et al.   EUROPEAN JOURNAL OF CANCER